Four leading institutions at the forefront of dengue prevention and control—the International Vaccine Institute (IVI), the International Vaccine Access Center (IVAC) of the Johns Hopkins University, the Partnership for Dengue Control Foundation (PDC) and
the Sabin Vaccine Institute have formed a new global alliance, which is named the Global Dengue and Aedes-transmitted Diseases Consortium (GDAC). This new partnership will integrate approaches to fight dengue and other Aedes-transmitted diseases including Zika, chikungunya and yellow fever.
GDAC will be working closely with the World Health Organization (WHO) to provide scientific evidence to facilitate comprehensive Aedes-transmitted disease control, incorporating research and public health projects, technical meetings and consultancies, regulatory and policy support, financing frameworks and communications and advocacy.
The key objectives of this alliance is to accelerate innovation and application of vaccines, vector control, antivirals, clinical management, therapeutics, diagnostics and surveillance, and licensure and post-marketing oversight of vaccines. In addition, GDAC
will focus on strengthening social mobilization, advocacy and capacity building. It will continue its members’ work with vaccine early adopter countries to develop integrated control strategies specific to those countries. GDAC will work with all stakeholders to
develop strategies designed to prevent outbreaks caused by other viruses transmitted by Aedes mosquitoes. With its global presence in Asia, America and Europe, GDAC will build a common agenda to lead the new era of Aedes-transmitted diseases prevention